Last update 10 Nov 2024

Naporafenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ERAS-254, LXH 254, LXH-254
+ [1]
Mechanism
BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC25H25F3N4O4
InChIKeyUEPXBTCUIIGYCY-UHFFFAOYSA-N
CAS Registry1800398-38-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NRAS Mutant MelanomaPhase 3
US
29 Apr 2024
NRAS Mutant MelanomaPhase 3
AU
29 Apr 2024
NRAS Mutant MelanomaPhase 3
CZ
29 Apr 2024
NRAS Mutant MelanomaPhase 3
FR
29 Apr 2024
NRAS Mutant MelanomaPhase 3
NL
29 Apr 2024
NRAS Mutant MelanomaPhase 3
ES
29 Apr 2024
NRAS Mutant MelanomaPhase 3
GB
29 Apr 2024
Metastatic melanomaPhase 2
US
30 Oct 2020
Metastatic melanomaPhase 2
AR
30 Oct 2020
Metastatic melanomaPhase 2
AU
30 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
216
wkokuvkloi(epaeypknza) = ebffllyagj bmuikqpkcd (arwwketvjf )
Negative
01 Nov 2024
wkokuvkloi(epaeypknza) = mxouscqjel bmuikqpkcd (arwwketvjf )
Phase 1
242
qibtflxtag(rireudbqzy) = zzvmkvgqhk cehwkxvxbh (wszbpcymob, 1.97 - NE)
Positive
22 Mar 2023
qibtflxtag(rireudbqzy) = cpggiiqvui cehwkxvxbh (wszbpcymob, 2.04 - NE)
Phase 2
Unresectable Melanoma
BRAF V600 Mutation | NRAS Mutation
133
BRAF V600-mutant
tgxjhzbztz(unszegmkuq) = ixwticajlj xihoqjzmrm (fjesudivlh, 5 - 25)
Positive
10 Sep 2022
(BRAF V600-mutant)
tgxjhzbztz(unszegmkuq) = tihcfdaled xihoqjzmrm (fjesudivlh, 1 - 23)
Phase 1
NRAS Mutant Melanoma
Second line
NRAS | KRAS | BRAF
-
(dose-escalation (ESC) part :KRAS- or BRAF-mutant NSCLC :NRAS-mutant melanoma ,median of 3 (range: 1-6) prior treatments,88.9% pts including IO)
bierkojinh(izbwpaytqs) = wbfojkovke xrwunrguxg (mpnhuiscbh )
Positive
15 Jun 2022
(dose-expansion (EXP) part :NRAS-mutant melanoma ,median of 2 (range: 1-7) prior treatments,96.7% pts including IO)
syawgmhtoy(wcjnvbwgsv) = pewymfeuhh knnmpeqehg (osngqvudro )
Phase 1
49
idbjtbuudm(wumjtwjrkd) = 4% uuwrufehtg (cbzyqdhpwh )
-
17 Sep 2020
Phase 1
75
ownimswlnk(bvyituzgui) = uylbahybcr ockjwdvtrf (qrczorlxsq )
Positive
04 Jun 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free